Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Allen Lutz | Bank of America | 8 questions · 0% challenging |
| Eric Percher | Nephron Research | 8 questions · 0% challenging |
| Erin Wright | Morgan Stanley | 8 questions · 0% challenging |
| Mike Cherny | Leerink Partners | 8 questions · 0% challenging |
| Elizabeth Anderson | Evercore ISI | 7 questions · 0% challenging |
| George Hill | Deutsche Bank | 7 questions · 0% challenging |
| Kevin Caliendo | UBS | 7 questions · 0% challenging |
| Daniel Grosslight | Citigroup | 7 questions · 0% challenging |
| Eric Coldwell | Robert W. Baird | 7 questions · 0% challenging |
| Steve Valiquette | Mizuho Securities | 6 questions · 0% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Bank of America | 1 analyst | 8 questions · 0% challenging |
| Evercore ISI | 2 analysts | 8 questions · 0% challenging |
| Leerink Partners | 1 analyst | 8 questions · 0% challenging |
| Morgan Stanley | 1 analyst | 8 questions · 0% challenging |
| Nephron Research | 1 analyst | 8 questions · 0% challenging |
| UBS | 1 analyst | 7 questions · 0% challenging |
| Robert W. Baird | 1 analyst | 7 questions · 0% challenging |
| Citigroup | 1 analyst | 7 questions · 0% challenging |
Calendar quarter Q1 2026Earnings call Apr 30, 2026
FY2026 Q3 in brief
Cardinal Health posted Q3 non-GAAP EPS of $3.17 representing 35% growth, with operating earnings up 18% despite a $184 million Navista goodwill impairment on the GAAP line.
Newest quarter FY2026 Q4 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Cardinal Health (CAH), FY2026 Q3: 9/10. Scores: Cardinal Health’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: CAH daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
Cardinal Health posted Q3 non-GAAP EPS of $3.17 representing 35% growth, with operating earnings up 18% despite a $184 million Navista goodwill impairment on the GAAP line. Full-year guidance was raised $0.50 at the midpoint to $10.70-$10.80, with adjusted free cash flow guidance also increased to $3.3-$3.7 billion. Specialty revenue exceeded 20% growth, and pharmaceutical distribution demand remained strong with 11% revenue growth.
Revenue Growth | Margin | Competitive Dynamics | Demand | Guidance Reliability | Trade Tariffs | M&A | Pricing | |
|---|---|---|---|---|---|---|---|---|
| 2025Q1 | 3 | 5 | 3 | 4 | 2 | 1 | 2 | |
| 2025Q2 | 2 | 3 | 3 | 4 | 1 | 2 | 3 | |
| 2025Q3 | 3 | 2 | 2 | 2 | 2 | 9 | 5 | |
| 2025Q4 | 1 | 9 | 1 | 1 | 6 | 1 | 2 | 1 |
| 2026Q1 | 6 | 1 | 4 | 2 | 2 | 3 | 1 | |
| 2026Q2 | 5 | 1 | 5 | 1 | 2 | 1 | 2 | 2 |
| 2026Q3 | 3 | 1 | 3 | 3 | 2 | 1 | 5 | 2 |
| '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | '26Q3 | |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 3 | 2 | 3 | 1 | 6 | 5 | 3 |
| Margin | 5 | 3 | 2 | 9 | 1 | 1 | 1 |
| Competitive Dynamics | 3 | 3 | 2 | 1 | 4 | 5 | 3 |
| Demand | 4 | 4 | 2 | 1 | 2 | 1 | 3 |
| Guidance Reliability | 2 | 1 | 2 | 6 | 2 | 2 | 2 |
| Trade Tariffs | 1 | 2 | 9 | 1 | 1 | 1 | |
| M&A | 3 | 2 | 3 | 2 | 5 | ||
| Pricing | 2 | 5 | 1 | 1 | 2 | 2 |
No 8-K events recorded for this window.
GAAP revenue YoY +11.1% → base 7. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2025 Q1 | $52.28B | -4.3% | $1.70 | +3500.0% | 3.6% | 1.1% | 0.8% | $-1.74B |
| FY2025 Q2 | $55.26B | -3.8% | $1.65 | +10.0% | 3.5% | 1.0% | 0.7% | $-499M |
| FY2025 Q3 | $54.88B | +0.0% | $2.10 | +96.3% | 3.9% | 1.3% | 0.9% | $2.79B |
| FY2025 Q4 | $60.16B | +0.8% | $1.00 | +4.2% | 3.7% | 0.7% | 0.4% | $1.29B |
| FY2026 Q1 | $64.01B | +22.4% | $1.88 | +10.6% | 3.6% | 1.0% | 0.7% | $865M |
| FY2026 Q2 | $65.44B | +18.4% | $1.97 | +19.4% | 3.4% | 1.1% | 0.7% | $555M |
| FY2026 Q3Selected | $60.94B | +11.0% | $1.69 | -19.5% | 4.1% | 0.8% | 0.7% | $1.68B |
| FY2026 Q4 | $63.86B | +6.1% | $1.69 | +69.0% | 4.3% | 1.1% | 0.6% | $1.43B |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
CAH Cardinal Health | 9 | +11.1% | |
| COR Cencora | 8 | +3.9% | |
| HSIC Henry Schein | 6 | +6.3% | |
| MCK McKesson Corporation | 8 | +6.0% |